HeartBeat.bio, a Vienna, Austria-based biotech company providing a human organoid and AI-supported drug discovery platform for heart disease, raised €4.5M in Pre-Series A funding.
The round was led by i&i Biotech Fund, Invest AG, aws Gründungsfonds II, and Tensor Ventures.
The company intends to use the funds to enable the completion of a cardioid drug discovery platform for proprietary and collaborative drug discovery programs in indications such as drug-induced and genetic cardiomyopathies, as well as myocardial infarction and fibrosis.
Led by CEO Michael Krebs, HeartBeat.bio is building a human organoid cultivation, screening and AI-supported data analysis solution for developing drugs to treat heart failure. The so-called cardioid drug discovery platform relies on self-assembling, highly reproducible cardiac organoids which recapitulate the human physiology and enable modeling of heart diseases in a way not achieved with other in-vitro systems. Currently, HeartBeat.bio is focused on drug-induced and different sub-types of genetic cardiomyopathies, followed by programs in diabetic cardiomyopathy, myocardial infarction, and cardiac remodeling.
FinSMEs
03/11/2023